Article thumbnail

Effect of Fluticasone propionate Aqueous Nasal Spray Treatment on Platelet Activating Factor and Eicosanoid Production By nasal Mucosa in Patients with A house Dust Mite Allergy

By I. M. Garrelds, T. de Graaf-in 't Veld, A. P. H. Jansen, R. Gerth van Wijk and F. J. Zijlstra


The relationship between the release of platelet activating factor (PAF), leukotriene C4/D4/EE (LTC4/D4/E4) and prostaglandin D2 (PGD2) from nasal mucosa in vivo was examined in 24 rhinitis patients allergic to the house dust mite (HDM). During a double blind placebo controlled cross-over study 200 μg fluticasone propionate aqueous nasal spray (FPANS) was administered twice daily for two weeks. In response to allergen provocation (100, 1 000, 10 000 Bu/ml) and during the 9.5 h after this challenge the nasal fluid was obtained by washing the nose with saline and the levels of PAF, LTC4/D4/E4 and PGD2, as indicators of mediator release, were measured at the following time-points: baseline (t = − 1/2), allergen provocation with 10 000 Bu/ml (t = 0), 3.5 and 7.5 h (late phase). After allergen provocation the levels of the mediators increased in the nasal fluids of placebo treated patients (x-fold increase to baseline: PAF, 15; LTC4/D4/E4, 12; PGD2, 1.5). In fluids of patients treated with FPANS these levels tended to decrease. At the time of provocation the levels of PAF, LTC4/D4/E4 and PGD2 showed a significant correlation. The results indicate that these mediators can be used as markers of allergic reactions against house dust mites and that fluticasone propionate aqueous nasal spray tended to reduce the release of mediators of inflammation correlated with beneficial effects on clinical symptoms in this type of allergic reactions

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1988). Activation of pulmonary mast cells by bronchoalveolar lavage allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am Rev Respir Dis
  2. (1988). Allergen-induced leukotriene production by nasal and peripheral blood leukocytes. Arch Otolaryngol Head Neck Surg
  3. (1987). Antigenic release of PAF-acether and glucuronidase from alveolar macrophages of asthmatics.
  4. (1987). Arachidonic acid metabolites during nasal challenge. Arch Otolaryngol Head Neck Surg
  5. (1968). Association (Research Committee). Treatment of house dust allergy. BrMedJ
  6. (1983). Biosynthesis and release of platelet-activating factor from human monocytes. Int Arch Allergy Appl Immunol
  7. (1983). Bronchial and nasal sensitivity changes during year of immunotherapy with mite extracts. Folia Allergol Immunol Clin
  8. (1988). Comparison of the production of eicosanoids by human and rat peritoneal macrophages and rat Kupffer cells. Prostaglandins
  9. (1988). Correlation between symptoms and the threshold for release of mediators in nasal secretions during challenge with grasspollen grains.
  10. Diagnosis of house dust mite allergy. Allergy 1991; 46(Suppl 11):
  11. (1989). Different pattern of arachidonate metabolism in autologous human blood monocytes and alveolar macrophages. Jlmmunol
  12. (1989). Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and immunological stimuli.
  13. (1921). Dust sensitization in bronchial asthma. Med Clin North Am
  14. (1987). Effect of short-term systemic glucocorticoid treatment human nasal mediator release after antigen challenge.
  15. (1991). Effects of 4 weeks treatment with the topical glucocorticoid fluticasone allergen-induced symptoms, tissue mast cells and histamine in the nasal XIVInt Congress ofAllergol and Clin Immunol
  16. (1989). Evidence of PAF-acether metabolic pathway activation in antigen challenge of upper respiratory airways. Am Rev Respir Dis
  17. (1983). Generation and metabolism of 5-1ipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C Proc Natl Acad Sci USA
  18. (1985). House dust mite allergy. Allergy
  19. (1980). Human neutrophil-derived platelet activating factor. JImmunol
  20. (1976). Hyposensitisation with house dust mite vaccine in bronchial asthma. BrMedJ
  21. (1992). Increase of albumin, eosinophil cationic protein, histamine, leukotrienes and mast cell tryptase in nasal lavage fluids after challenge with inhalant allergen extract. Agents Actions
  22. (1984). Increased biosynthesis of platelet activating factor from activated human eosinophils. JBiol Chem
  23. (1986). Inflammatory mediators in nasal secretions during induced rhinitis. Clin Allergy
  24. (1992). Intranasal fluticasone propionate; review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in allergic rhinitis. Drugs
  25. (1992). Isolated early response after nasal allergen challenge is sufficient to induce nasal hyperreactivity. Ann Allergy
  26. (1988). Leukotriene C and histamine in early allergic reaction in the Allergy
  27. (1988). Local cellular and humoral responses to antigenic and distilled water challenge in subjects with allergic rhinitis. Am Rev RespirDis
  28. (1983). Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis
  29. (1991). Mediators and allergic rhinitis. ClinExp Allergy
  30. Mediators of allergic rhinitis.
  31. (1985). Mediators release after allergic and physical nasal challenges. IntArchs AllergyApplImmun
  32. (1993). Nasal hyperreactivity and its effects early and late sequela of nasal challenge with house dust mite extract. Allergy Proc
  33. (1991). Nasal inflammatory mediator release in ragweed allergic rhinitis: correlation with cellular influx into nasal secretions. Int Archs Allergy Appl Immun
  34. (1984). Physiological and pharmacological regulation of prostaglandin and leukotriene production by macrophages. JLeukocyte Biol
  35. (1980). Platelet activating factor (PAF-acether) secretion from platelets. Effect of various aggregating agents. BrJ Haematol
  36. (1986). Platelet-activating factor: potent chemotactic and chemokinetic factor for human eosinophils. JClin Invest
  37. (1984). Preferential generation of leukotriene C by human eosinophils. Clin Exp Immunol
  38. (1961). Preliminary studies Dermatophagoides farinae Hughes,
  39. (1990). Release of leukotriene C (LTC4) from human eosinophils following adherence to IgE- and IgG-coated schistosomula of Schistosoma mansoni. Immunology
  40. (1980). Skin testing. In: Rose NR, Friedman Heds. Manual of clinical immunology. 2nd edn.
  41. (1964). Spieksma FThM. Is mite (Dermatophagoides sp.) the producer of the house-dust allergen? Allergie Asthma
  42. Structure-activity relationships of topical active steroids; the selection of fluticasone propionate. Respir Med 1990; 84(Suppl A):
  43. (1977). Study of prolonged hyposensitization with D. pteronyssinus extract in allergic rhinitis. ClinAllergy
  44. The cellular response of the human allergic to natural allergen exposure. JAllergy Cltn Immuno11988;
  45. The effect of topical fluticasone propionate allergen-induced immediate nasal airways response and eosinophil activation: preliminary results. RespirMed 1990; 84(Suppl A):
  46. The effects of intranasal fluticasone propionate allergen induced nasal provocation. Clin InvestMed 1989; 12($uppl 4):
  47. (1967). The house dust mite (Dermatophagoidespteronyssinus) and the allergen it produces. Identify with the house-dust allergen. JAllergy
  48. (1988). The pathophysiology of allergic rhinitis: Impact of therapeutic intervention. JAllergy Clin Immunol
  49. (1983). The release of platelet-activating factor from human endothelial cells in culture. JImmunol
  50. (1987). Topical steroid pretreatment inhibits mediator release in vivo. JEnglJMed